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Abstract

ACCEPTED MANUSCRIPT
Stroke is the second leading cause of death globally and represents a major cause of
devastating long-term disability. Despite sustained efforts to develop clinically effective
neuroprotective therapies, presently there is no clinically available neuroprotective agent for
stroke. As a central mediator of neurodamaging events in stroke, mitochondria are recognised
as a critical neuroprotective target, and as such, provide a focus for developing
mitochondrial-targeted therapeutics. In recent years, cationic arginine-rich peptides (CARPs)
have been identified as a novel class of neuroprotective agent with several demonstrated

PT

mechanisms of action, including their ability to target mitochondria and exert positive effects
on the organelle. This review provides an overview on neuronal mitochondrial dysfunction in

NU

SC

mitochondria in the ischaemic brain following stroke.

RI

ischaemic stroke pathophysiology and highlights the potential beneficial effects of CARPs on
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1.

Stroke Background: Epidemiological ‘Snapshot’ and Need for Neuroprotection

ACCEPTED MANUSCRIPT
Acute stroke is a global epidemic responsible for the second and third leading causes of death
and disability respectively [1, 2]. In 2010, the global prevalence of stroke was estimated to be
approximately 33 million, with 16.9 million individuals experiencing their first stroke [3]. A
significant proportion of stroke survivors are left with cognitive and physical disabilities [4,
5], or impaired language and verbal communication [6]. The burden of stroke to the global
community is continuing to increase due to the aging world population and the increasing
prevalence of risk factors for stroke, such as hypertension [7], diabetes [8], hyperlipidaemia

PT

[9], heart disease [10], obesity [11] and reduced physical activity [12–14]. As an increasing
risk factor, the aging world population is a major concern [15], with approximately 900

RI

million people aged over 60, rising to an expected 1.5 billion by the year 2050 [16]. To make

SC

matters worse, there are currently no clinically available neuroprotective agents for the acute
treatment of stroke to minimise brain injury, and current therapies are mainly restricted to

NU

endovascular recanalisation interventions for a selected subgroup of ischaemic stroke
patients. However, most patients are ineligible for such interventions due to narrow
therapeutic time windows (e.g. 4.5h for tPA thrombolysis) and/or the need for specialised

MA

tertiary hospital facilities to perform the procedure (e.g. mechanical thrombectomy).
Notwithstanding, the recent DAWN and DEFUSE 3 clinical trials demonstrated that

ED

thrombectomy, when performed up to 16 to 24 hours post-stroke symptoms, could improve
outcomes in a subgroup of patients selected on the basis of the presence of potentially
salvageable penumbral tissue [17, 18]. For this reason it is now recommended that a “tissue

EP
T

window” rather than a “time window” be used when considering therapeutic interventions,
such as thrombectomy and neuroprotection. Furthermore, it highlights the need for a safe
neuroprotective agent that can be administered early after stroke onset to slow brain
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C

infarction and preserve penumbral tissue.

Consequently, there is an urgent requirement for the development of new and more widely
applicable neuroprotective therapies that lessen the neurological impact of stroke and
increase the number of patients eligible for endovascular treatments. To this end, due to the
lack of success in the past, there is growing sentiment that new approaches in the discovery
and development of acute neuroprotection therapies will be required.

The main purpose of this review is to examine the role of mitochondrial dysfunction in stroke
pathophysiology, and in doing so highlight the beneficial effects that neuroprotective cationic
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arginine rich peptides (CARPs) may exert on mitochondria in neurons in the ischaemic brain
following stroke.

2.

Mitochondrial Dysfunction in Stroke Pathophysiology

2.1

Underlying stroke injury mechanisms: The ischaemic cascade

PT

Ischaemic stroke results from the acute occlusion of a cerebral artery by thrombosis or
embolism, and constitutes the bulk of stroke events, accounting for approximately 80% of

RI

cases [19], and as such, will be the main focus of this review. Ischaemic stroke
pathophysiology is initiated by a sudden reduction in blood flow to the affected brain tissue,

SC

causing a deficiency in oxygen and glucose supply, triggering what is known as the
ischaemic cascade (Figure 1) [20, 21]. The ischaemic cascade is influenced by the duration

NU

and severity of ischaemia [22], which usually culminates in the time-dependent death of
neuronal tissue. Acute injury occurs within minutes in severely affected brain tissue in the

MA

ischaemic core, which represents an area of infarcted or irreversibly damaged brain tissue,
and cannot be salvaged. Surrounding the ischaemic core is the potentially salvageable tissue
known as the penumbra, which is affected by ischaemia, although to a lesser extent than in

ED

the core, and consequently has not succumbed to cell death. Brain injury in the penumbra can
proceed over many hours, and is the target of endovascular recanalisation interventions (tPA
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and thrombectomy) and neuroprotective treatments. However, in the absence of adequate
reperfusion or a neuroprotective therapy, the on-going and cumulative cellular injury,
including the demise of mitochondria, reaches a critical threshold, and neurons become
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irreversibly committed to dying and are incorporated into the ischaemic core.

Mitochondria are key regulators in determining the fate of ischaemic brain tissue, as they are
both

affected

mitochondrial

by and

disturbances

are propagators of ischaemic
have

also

been

identified

injury.
as

key

Furthermore,
contributors

neuronal
to

the

pathophysiology of several chronic neurological disorders, including Parkinson’s disease
[23], Alzheimer’s disease [24], and Huntington’s disease [25–33]. Another consideration is
that mitochondrial bioenergetics naturally decline with age, largely as a result of accumulated
oxidative damage to mitochondrial DNA, proteins, and lipids [34–37]. As a consequence,
aged mitochondria are more likely to be vulnerable to the effects of cellular energy
disturbances, as occurs in ischaemic stroke [38]. This has additional implications in stroke, as
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most strokes occur in individuals over the age of 65 [39], and age-related decline in
mitochondrial function may result in an increased susceptibility to ischaemic brain injury. In
this context, mitochondria represent critical targets for the development of neuroprotective
strategies for stroke and other neurological disorders, and as such, their role in the ischaemic
cascade is described in detail below.

Biomolecular mechanisms underlying mitochondrial dysfunction during stroke

PT

2.2

Energy failure and excitotoxicity: Glutamate and calcium

RI

During ischaemic stroke, neuronal mitochondrial function is severely compromised due to the

SC

reduced availability of glucose and oxygen necessary for ATP production, a situation which
is exacerbated by the high energy demand of neuronal tissue [40, 41]. The resulting
to

the

mitochondrial

electron

transport

chain

(ETC)

halts

oxidative

NU

disruption

phosphorylation, forcing cells to rely on anaerobic glycolysis for ATP production [42].
However, due to the limited supply of glucose, glycolysis is also severely compromised.

MA

Since ATP is required for the maintenance of ion gradients across neuronal plasma
membranes [43], the resulting energy failure triggers the depolarisation of neurons and

ED

uncontrolled release of excitatory neurotransmitters, in particular glutamate, from presynaptic neurons [42]. High extracellular levels of glutamate cause excitotoxicity due to the
overstimulation of post-synaptic glutamate receptors [44, 45], including N-methyl-D-
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aspartate (NMDA) and -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
receptors, thereby causing prolonged depolarisation and toxic accumulation of calcium and
sodium within neurons [46–48] (Figure 1). High levels of intracellular calcium are
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particularly toxic to neurons due to its involvement in the activation of proteolytic enzymes
and lipases, free radical formation and oxidative stress, mitochondrial dysfunction, cell death
signalling, and cytotoxic oedema [47, 49–52]. It is therefore not surprising that the inhibition
of excitotoxic intracellular calcium influx is invariably neuroprotective [53–56].

Mitochondria and intracellular calcium
As a consequence of excitotoxic intracellular calcium disturbances, mitochondria can act as a
buffer to help regulate cytosolic calcium concentrations and minimise toxic effects [57–60].
Mitochondria sequester calcium through several mechanisms including the mitochondrial
calcium uniporter (MCU) [59–61], mitochondrial sodium-calcium exchanger (mNCX) [62],
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voltage-dependent anion channel (VDAC) [63], “rapid-mode” of uptake (RaM) [64], and the
mitochondrial-located ryanodine 1 receptor (mRyR) [65, 66] (Figure 1). However, during
severe

excitotoxicity

and

ongoing

ionic

disturbances,

the

buffering

capabilities

of

mitochondria can become overwhelmed, leading to excessive intra-mitochondrial calcium
concentrations and disruption of mitochondrial function [67, 68]. Although mitochondria are
capable of extruding excess calcium via the mNCX, this exacerbates the toxic cytosolic
calcium loading [69, 70]. Mitochondria also co-operate with the endoplasmic reticulum (ER)

PT

to help maintain cellular calcium homeostasis via the mitochondria-associated ER membrane
(MAM), allowing the organelles to collaborate in calcium ion exchange [71]. In spite of this,

RI

the ER can be an additional source of cytosolic calcium following release of excess calcium

SC

via the ryanodine (RyR) and inositol triphosphate (IP 3 R) receptors [72]. Furthermore,
cytochrome c (cyt c), a protein involved in the mitochondrial ETC and apoptosis, is released

NU

from dysfunctional mitochondria and can translocate to the ER to selectively bind IP3 Rs
(Figure 1), causing prolonged release of calcium from the organelle, and thereby sustaining a
toxic feedback loop know as calcium-induced calcium release (CICR) [73]. Ultimately, the

MA

excessive and sustained intra-mitochondrial accumulation of calcium significantly impacts
mitochondrial function, and is a potent trigger for mitochondrial reactive free radical species

ED

generation, which further impacts the function of the organelle and cell viability (Figure 2).

Oxidative and nitrosative stress and mitochondria
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Stroke is associated with oxidative stress resulting from the overproduction of reactive
oxidative species (ROS) and reactive nitrosative species (RNS), which overwhelms
endogenous neuronal antioxidant defence mechanisms, leading to damage to cellular
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components [74]. During stroke, mitochondria generate an initial burst of ROS, including
superoxide anion (O 2 •-), hydroxyl radical (•OH), and hydrogen peroxide (H2 O2 ) [75–78].
Such oxidants cause considerable damage to brain tissue due to the brain’s large
polyunsaturated fatty acid composition and limited antioxidant defensive capabilities [79].
Mitochondrial ROS generation is primarily derived from the ETC, with complexes I and III
generating the bulk of ROS through ‘electron leak’ [80]. Auto-oxidation of ‘leaked’ electrons
to oxygen forms the free oxygen radical O2 •- [75, 81], which is converted into H2 O 2 by
endogenous manganese superoxide dismutase (MnSOD) [82]. Mitochondrial catalase and
peroxiredoxin can convert H2 O2 into H2 O [83]. However, the abundance of iron sulfur
clusters and iron containing heme groups associated with ETC proteins, such as those present
in complexes I, II and III [84], provide a bountiful source of iron for generation of •OH from
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H2 O 2 via the Fenton reaction [85] (Figure 2). Mitochondria are also major contributors to the
ROS generation that occurs during spontaneous reperfusion or following therapeutic
endovascular recanalization after stroke. Although timely restoration of cerebral blood flow is
of primary importance in preventing further injury during stroke, the sudden reoxygenation of
brain tissue can trigger what is known as ‘reperfusion injury’. Reperfusion reintroduces
molecular oxygen to oxygen-starved tissue and provides a fresh source of substrates causing
a surge in ROS formation [75], which places additional stress on mitochondria already

PT

affected by ischaemia.

RI

Mitochondria are also the target of RNS due to the excessive production of nitric oxide (NO•)

SC

during stroke [86, 87]. NO• plays an important role in excitotoxicity-mediated injury and is
generated through neuronal nitric oxide synthase (nNOS) linked to neuronal NMDA receptor
signalling [88]. During overactivation of NMDA receptors, calcium influx activates nNOS,

NU

producing NO•, which then interacts with mitochondrial-generated O2 •- to produce the highly
volatile peroxynitrite species (ONOO -) [89–91]. Both NO• and ONOO - react with

MA

mitochondrial membranes and other lipid membranes, as well as eliciting S-nitrosylation and
activation of pro-death proteins, including caspases and matrix metalloproteinases [89, 92,

ED

93] (Figure 2). Furthermore, ROS/RNS-induced damage of ETC components, particularly the
ETC anchoring phospholipid, cardiolipin, exacerbates ROS generation arising from enhanced
electron ‘leak’, resulting in mitochondria not only acting as propagators of ROS formation,
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but also targets of ROS-induced injury [94, 95].

Free radical oxidation of cardiolipin is particularly detrimental as the phospholipid plays an
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important role in maintaining inner mitochondrial membrane (IMM) structure and anchoring
ETC complexes to the IMM to ensure optimal mitochondrial bioenergetics [96, 97].
Furthermore, due to cardiolipin’s high unsaturated fatty acid content and its close proximity
to the site of mitochondrial ROS production, it is highly susceptible to oxidative damage [95].
As a consequence, oxidised cardiolipin can lead to further destabilisation of the ETC, as well
as promoting the detachment of cyt c from the IMM and its release from mitochondria [98].
Furthermore, the interaction of oxidised cardiolipin with cyt c bestows peroxidase activity to
the protein capable of catalyzing H2 O2 -dependent peroxidation, causing further oxidation of
cardiolipin [99].
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Together, excessive mitochondrial ROS/RNS generation perpetuates cellular injury by
attacking mitochondrial and cytoplasmic lipid membranes, proteins and DNA, causing
cellular damage that contributes to neuronal cell death [100–102].

The mitochondrial membranes and mitochondrial membrane potential
The outer mitochondrial membrane (OMM) is a selectively permeable phospholipid bilayer
that controls the transport of substances in and out of the organelle via membrane-bound

PT

transporter complexes. For example, the OMM voltage-dependent anion channel (VDAC)
facilitates the exchange of various ions and small uncharged molecules [103]. Similarly,

RI

selective cytosolic protein and peptide import across the OMM is achieved via multi-subunit

SC

conductor complexes known as ‘translocase of outer mitochondrial membrane’ (TOM)
channels [104]. The inner mitochondrial membrane (IMM) is also a phospholipid bilayer that

NU

is extensively folded and is embedded with proteins comprising the ETC, as well as other
conductance protein channels known as ‘translocase of the inner membrane’ (TIMs), which
form a supercomplex with TOMs that communicate across the intermembrane space, and are

MA

responsible for the exchange of pre-proteins from the intermembrane space into the
mitochondrial matrix [105, 106]. Crucially, the ETC is responsible for generating the

ED

electrochemical gradient across the IMM, known as the mitochondrial membrane potential
(Δψm), which is necessary for energy production via oxidative phosphorylation [107] (Figure
2). The Δψm is an integral part of the proton motive force (p) generated by the ETC and
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used by ATP synthase to generate ATP [108, 109]. The Δψm is also critical for mitochondrial
function and cell viability, as it is a primary factor that determines mitochondrial respiration,
calcium sequestration capacity, and ROS production, all of which play a critical role in
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determining the fate of neurons during ischaemia [110].

During stroke, the excessive accumulation of calcium in the mitochondrial matrix can trigger
hyperpolarization, and subsequently depolarization of the IMM and dissipation of the Δψm
[78], leading to impaired ATP production [111, 112]. In an attempt to maintain the multitude
of Δψm-dependent processes critical for mitochondrial function, mitochondrial ATP synthase
acts in reverse (F1Fo-ATPase) and hydrolyzes ATP to conserve the Δψm. However, due to
the ongoing effects of ischaemia, the depletion of mitochondrial and cytosolic ATP further
exacerbates loss of mitochondrial integrity and activation of cell death cascades [113, 114]. It
is considered that the complete dissipation of the Δψm in a large proportion of mitochondria
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within a cell is one of the earliest indicators of irreversible cell death [115]. It is for these
reasons that interventions that restore and/or preserve the Δψm can improve the likelihood of
cell survival, and therefore represent potent therapeutic interventions for neuroprotection
[116–118].

Mitochondrial outer membrane permeabilization and cell death signalling
Neuronal

mitochondrial

dysfunction

culminates

in

mitochondrial

membrane

PT

permeabilization, which is a critical event in promoting pro-death signalling pathways via the
release of cell death-promoting molecules from the intermembrane space into the cytosol.

RI

Mitochondrial-mediated cell death can proceed by two different mechanisms depending on

SC

either apoptotic or necrotic stimuli (see comprehensive reviews by [119, 120]). Classic
mitochondrial-mediated apoptotic cell death is instigated by the recruitment of pro-death Bcl-

NU

2 family member proteins, Bad and Bax, to the OMM [121]. Oligomerization of Bad and Bax
in the OMM triggers mitochondrial outer membrane permeabilization (MOMP), which
releases pro-apoptotic factors such as cyt c [122], apoptosis inducing factor protein (AIF)

MA

[123, 124], second mitochondria-derived activator of caspase/direct inhibitor of apoptosis
protein (IAP)-binding protein with low pI (Smac/DIABLO), and endonuclease G (Endo G)

ED

[125] from the intermembrane space into the cytosol [126]. The release of the pro-cell death
factors together orchestrates an interconnected process resulting in the dismantling of cell

EP
T

structures, contributing to the demise of the cell [127] (Figure 1).

Additionally, mitochondria play a role in necrotic cell death associated with elevated ROS
generation and mitochondrial calcium loading. The toxic effects of ROS and calcium influx
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on mitochondria causes permeabilization of the IMM, known as permeability transition (PT),
and results in the formation of the highly conductive mitochondrial permeability transition
pore (mPTP) spanning the inner and outer mitochondrial membranes. The mPTP facilitates
influx of calcium and other solutes into the mitochondrial matrix [128, 129]. Sustained mPTP
conduction also contributes to mitochondrial ROS release [130], which in turn maintains
mPTP opening in a self-propagating cycle known as ROS-induced ROS release (RIRR) (see
review [78]). Influx of calcium into the matrix causes equilibration of the proton gradient and
collapse of the Δψm, further enhancing ROS generation and metabolic inhibition [131, 132].
Furthermore, the increasing osmotic pressure from mitochondrial calcium accumulation
causes the matrix to swell beyond the limits of the OMM, eventually rupturing the OMM and
liberating calcium in addition to the aforementioned mitochondrial pro-death factors into the
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cytosol. This stimulates proteases, nucleases, and lipases, causing subsequent degradation of
cellular proteins, DNA, and membrane lipids, leading to necrotic cell death [133, 134].

Mitochondrial fusion and fission
As an adaptive response to metabolic and oxidative stress, mitochondria can rapidly alter
their structural architecture through a process of fusion and fission. Mitochondrial fusion
involves the joining of mitochondria in order to allow compensatory functions between

overall mitochondrial integrity

[136,

137].

Fused

PT

healthy and metabolically challenged mitochondria [135], and thereby helps to preserve
mitochondria

have a filamentous

RI

morphology comprising a large interconnected metabolic network that can span over a

SC

hundred microns across a single cell to enable the supply of ATP to energy-deficient cellular
regions [138–140]. The ability of mitochondria to fuse is particularly important in the context

of dysfunctional mitochondria

without

NU

of post-mitotic cells, such as neurons, as it provides a means of minimising the toxic effects
triggering

cell death

[35].

The

process

of

mitochondrial fusion is controlled through the actions of the dynamin GTPase family

MA

members, mitofusins (Mfn1, Mfn2) and optic atrophy 1 (Opa1), which act on the OMM and

ED

IMM, respectively [141].

Similarly, mitochondrial fission represents a mechanism whereby the organelle can divide in
an attempt to segregate mitochondrial damage, and eliminate dysfunctional mitochondria by
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mitophagy. Mitochondrial fission is mediated by the dynamin GTPase family member, Drp1
[142], as well as Fis1 [143], which act on the OMM and IMM respectively. However,
mitochondrial fragmentation resulting from excessive mitochondrial fission, as well as the
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altered ability of cells to undergo mitochondrial fission, have been linked to neuronal injury
and neurodegeneration [144–146].

With respect to stroke-mediated injury, NMDA receptor overactivation of cultured neurons is
associated with excessive mitochondrial fragmentation, and promotion of mitochondrial
fusion reduces excitotoxic cell death [147]. Similarly, Drp1 inhibition, which blocks
mitochondrial fragmentation, reduces cell death in cortical neuronal cultures subjected to
glutamate excitotoxicity [148]. In addition, it has been demonstrated in HeLa cells that the
release of cyt c from mitochondria is accelerated as a consequence of down-regulation of
OPA1, a dynamin-like GTPase required for mitochondrial fusion, and precedes mitochondrial
fragmentation [149], indicating a temporal link between induction of mitochondrial pro-death
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signalling

and

mitochondrial fragmentation.

This is corroborated

by several reports

demonstrating mitochondrial fragmentation coinciding with ischaemic neuronal injury [150–
153]. Taken together, it appears that strategies that promote mitochondrial fusion or inhibit
excessive fission represent potential neuroprotective interventions to minimize neuronal
death following stroke and possibly other acute and chronic neurodegenerative disorders.

CARPs as Mitochondria-Targeted Neuroprotective Therapeutics

3.1

Neuroprotection in stroke and CARPs: A brief history

RI

PT

3.

capacity to

SC

In the context of stroke, a ‘neuroprotective agent’ refers to any compound that has the
slow and/or halt the progression of infarct development by inhibiting

NU

neurodamaging processes and/or by stimulating cell survival pathways [154]. To date, while
over 1000 novel potential neuroprotective therapeutics have been identified, many of which
demonstrated efficacy in preclinical animal studies [155], none have returned positive

MA

outcomes in clinical trials. While there are many reasons for previous failures to translate into
clinical efficacy (e.g. late administration of the agent after stroke, undesirable side-effects,

ED

ineffective drug targets, single pathway/mechanism of action, and study design), as
mitochondria are a central component in many of the critical aspects of the ischaemic
cascade, they represent a key target in the development of neuroprotective strategies. To this
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end, a class of inherently neuroprotective peptides, known as CARPs have emerged as
candidates for mitochondria-targeted therapeutics in stroke and other acute and chronic CNS

[156–162].

3.2

AC
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disorders, as well as ischaemic injury in other tissues, including myocardial and renal tissue

Features and membrane-traversing properties of CARPs

CARPs typically range in size from 4 to 30 amino acids, and are positively charged due to the
presence of cationic arginine residues, as well as cationic lysine and to a lesser extent
histidine residues [163, 164] (Table 1). An important feature of CARPs is their ability to
traverse cell membranes and enter cells and mitochondria, and for this reason they are also
known as cell-penetrating peptides (CPPs) [165]. The ability of CARPs to traverse cell
membranes is a direct result of peptide arginine content, namely the positive charge provided
by the guanidinium head that is unique to the arginine amino acid [166–169]. To this end, the
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guanidinium head group can form bidentate hydrogen electrostatic interactions with sulphate
(e.g. in heparin sulphate proteoglycans), phosphate (e.g. in phospholipid head groups) and
carboxylate (in phospholipid phosphatidylserine and protein receptors) moieties present on
the plasma membrane or organelle membrane structures, such as those present in
mitochondria, Golgi apparatus, endoplasmic reticulum, or the nucleus [170–174]. The
electrostatic interactions between arginine residues and anionic structures present on
membranes is a critical requirement for CARPs to cross typically impervious membranes,
164, 175, 176], via both endocytic (e.g.

PT

including the blood-brain barrier [163,

macropinocytosis, caveolin/lipid-raft-mediated and clathrin-mediated endocytosis) [177, 178]

RI

and non-endocytic (e.g. passive diffusion, inverted micelle) mechanisms [173, 179–182].

SC

CARP membrane-traversing efficacy is dependent on peptide arginine content, by increasing
peptide positive charge and guanidinium head group electrostatic interactions with membrane

NU

anionic moieties. This was demonstrated by significantly reduced translocation capabilities of
the TAT CPP when arginine residues were replaced with the alternative cationic amino acids,

MA

ornithine, histidine, and lysine, which are less basic compared to arginine and lack a
guanidinium head group [183]. Furthermore, peptide cellular uptake was enhanced when the
arginine content was increased [184]. With respect to arginine content and peptide length,

ED

CARP transduction efficiency across the plasma membrane, at least for poly-arginine
peptides, is detectable with R6 (6 mer arginine) and peaks with R15 [183]. In addition, CARP
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membrane-traversing capabilities can be enhanced by presence of other residues, particularly
the hydrophobic amino acid, tryptophan [185], and a high transmembrane potential [186].
The cell penetrating properties of CARPs are particularly useful in the context of
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neuroprotection, as one of the main obstacles in drug delivery to the CNS is transport across
the blood-brain barrier and entry into the brain.
Interestingly, and of particular importance in the context of mitochondria-targeted peptides, is
that the presence of a transmembrane potential is a crucial element for ability of guanidiniumrich CARPs to traverse membranes [186]. Regarding mitochondria, the Δψm [163, 166, 187]
and

the

presence of the

negatively charged

mitochondrial membrane phospholipid,

cardiolipin [188], provides the ideal electrostatic attractive forces that enable CARPs to target
this organelle. The guanidinium head groups of CARPs is also the likely source of their
antioxidant capabilities, due to their innate free radical scavenging properties [189–192],
making them perfectly suited to combat mitochondrial-generated ROS and/or cytosolic ROS
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originating from membrane-bound NADPH oxidase during ischaemia [193], which is
encouraged by the deleterious crosstalk between the two sources [194, 195].
By targeting mitochondria, CARPs can exert mito-protective effects on the organelle and by
extension help maintain cell viability during times of stress, as occurs following ischaemia
[196]. To date, a number of CARPs have been shown to target mitochondria, and have been
examined in stroke and other brain injury models (Figure 3, Table 2), several of which are

PT

discussed in detail below. It should be noted that while they are outside the scope of this
review, there are several non-peptide neuroprotective agents that potentially overlap

RI

mechanistically with CARPs by way of their guanidinium head groups, including metformin,

Pharmacokinetics of CARPs

NU

3.3
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phenformin and agmatine [197–201].

While free CARPs are likely to have a serum half-life of several minutes, CARPs bound to

MA

serum proteins are likely to have a serum half-life of several hours [202–205]. For example,
serum proteins such as albumin and α1-acid glycoprotein bind CARPs, providing a reservoir
of the peptide that prolongs serum half-life and potentially extending peptide therapeutic

ED

duration [203, 206, 207]. Furthermore, various peptide structural modifications such as
cyclization and use of D-enantiomer amino acids can enhance resistance to serum proteases,
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and thus improve serum stability [206, 208, 209]. With regards to tissue targeting, CARPs
and CARP-conjugates generally exhibit preferential distribution in kidney, liver, spleen, lung
and to a lesser extent brain [203, 204, 210–216]. While the ability of CARPs to target brain
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tissue is relatively modest, this may be advantageous in terms of reducing undesirable
neurological side effects, while still providing the desired therapeutic effects [203].
Furthermore, the increased permeability of the blood-brain barrier during ischaemic stroke is
likely to increase uptake into the brain and prolong the presence of CARPs within ischaemic
tissue [217].

3.4

Non-mitochondrial neuroprotective mechanisms of CARPs

There is growing evidence that CARPs, in addition to possessing mito-protective properties
are plurifunctional in terms of their neuroprotective mechanisms of action. For example,
studies in our laboratory have demonstrated that CARPs, including the TAT-fused NA-1

ACCEPTED MANUSCRIPT
peptide (TAT-NR2B9c), have the capacity to not only reduce glutamic acid induced
excitotoxic neuronal death and intracellular calcium influx [160, 161, 218–220], but also
reduce neuronal surface expression of the NMDA receptor subunit protein NR2B [221].
CARPs also have the capacity to reduce the activity and/or surface expression of other ion
channels and receptors (e.g. AMPAR, NCX, TRPV1, CaV2.2, CaV3.3) that may exacerbate
excitotoxic ionic disturbances in the brain following stroke [221–231], and is one likely
mechanism whereby the peptides reduce the damaging effects of glutamate-induced

PT

excitotoxicity. In addition to the confirmed neuroprotective properties of CARPs, they
possess other properties that may be beneficial following stroke; they induce the

[189–192],

inhibit

the

activity

of the proteasome

[232–234],

reduce

SC

peroxidation

RI

internalization of cell surface TNF receptors [231], scavenge free radicals and reduce lipid

inflammatory responses [235–241], activate pro-cell survival signalling [218, 229, 242], and

3.5

NU

inhibit pro-protein convertases that activate matrix metalloproteinases [243–245].

Preclinical and clinical efficacy of CARPs as mitochondria-targeted therapeutics

MA

for stroke

ED

Szeto-Schiller (SS) peptides

Szeto-Schiller (SS) peptides possess cytoprotective and mitoprotective properties and consist
of four amino acids in length, with a net positive charge of +3 due to the presence of one
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T

arginine and one lysine or ornithine residue, and C-terminal amidation [246]. The SS peptides
are synthesised with alternating cationic and aromatic residues, with five peptides being best
characterised (SS-01: YrFK-NH2 ; SS-02: DmtrFK-NH2 , SS-20: FrFK-NH2 ; SS-31: rDmtKF-
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NH2 ; mtCPP-1: rDmtOF-NH2 ; r = D-arginine, Dmt = 2,6-dimethyltyrosine, O = ornithine). It
is likely that the combination of the arginine residue and cationic charge are the reason that
SS peptides are able to traverse plasma and mitochondrial membranes.

In vitro studies examining the cytoprotective properties of SS-peptides have revealed several
potential mechanisms of actions. With respect to mitochondrial targeting, it has been
estimated that SS peptides can translocate within mitochondria at a 100-5000-fold higher
concentrations compared to the extramitochondrial cytosolic compartment [247, 248].
Furthermore, SS peptides concentrate in the IMM, where they are believed to interact with
and stabilize cardiolipin during oxidative stress, and thereby help preserve the IMM
bioenergetics and reduce ROS production [249]. In addition, the ability of SS peptides to
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target and stabilise IMM cardiolipin is considered a mechanism that inhibits disengagement
of cyt c from cardiolipin and its release from mitochondria into the cytosol [248, 250]. While
the exact mechanisms for the beneficial effects of SS peptides on IMM cardiolipin are not
fully known, the ability of the cationic guanidinium group present on arginine residues to
interact with anionic phosphate groups of cardiolipin (−2 net charge) may be involved.

There is also evidence that SS peptides have direct antioxidant properties, which would also

PT

reduce mitochondrial ROS levels. For example, in vitro studies have demonstrated that SS-31
quenches the ROS H2 O2 , •OH and ONOO -, and SS-02 quenches H2 O2 [248, 251]. The ROS-

RI

quenching effects of SS-31 have been demonstrated in a mouse model of hypertensive

SC

cardiomyopathy [252], and its ability to restore mitochondrial ATP production has also been
shown in a murine model of ischaemic kidney injury [157]. Furthermore, positive results with

NU

SS-31 have been obtained in a mouse stroke model, as demonstrated by Cho et al. (2007)
whereby intraperitoneal administration of SS-31 (2 and 5 mg/kg; 3000 and 7150 nmol/kg)
immediately, as well as 6, 24, and 48 hours after a 30 minute duration of MCAO significantly

MA

reduced infarct volume [253].

ED

The most recently developed SS peptide, mtCPP-1, has superior mitochondrial uptake and
superoxide scavenging abilities than SS-31 [254]. The mtCPP-1 peptide differs from SS-31
by the substitution of the lysine (K) residue with an ornithine (O) residue. While no
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explanation has been provided for the improved mito-protective effects of mtCPP-1 over SS31, Rigobello et al. (1995) demonstrated in isolated rat liver mitochondria that the ornithine
tetramer (OOOO; O4) was more effective than the lysine tetramer (KKKK) at maintaining
permeability
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mitochondrial

transition

and

membrane

potential

induced

by

calcium.

Importantly, the arginine tetramer (RRRR; R4) was even more effective than O4 at inhibiting
the toxic effects of calcium on mitochondrial permeability transition and membrane potential
[255], which further highlights the critical importance of arginine content for the mitoprotective benefits of CARPs.

Poly-arginine and related CARPs
In addition to SS peptides, longer chain CARPs, including poly-arginine peptides and cell
penetrating peptides (CPPs), exhibit neuroprotective properties [219, 256, 257]. Initial reports
from our laboratory and other laboratories demonstrated that the cationic arginine-rich CPP,
TAT48-57 (TAT: GRKKRRQRRR; net charge +9; arginine residues 6), displayed modest

ACCEPTED MANUSCRIPT
neuroprotective actions in both in vitro and in vivo stroke models [256, 258–261]. These
findings were in line with an earlier study by Ferrer-Montiel et al (1998), demonstrating that
cationic arginine-rich hexapeptides (net charge +3 - +7; Arginine residues 2 - 6) were
neuroprotective in a hippocampal neuronal NMDA excitotoxicity model [262]. Subsequent
studies in our laboratory showed that poly-arginine-9 (R9; 9 mer of arginine) and penetratin
were 17-fold and 4.6-fold respectively, more neuroprotective than TAT in a cortical neuronal
glutamate excitotoxicity model [256]. Further studies in our laboratory revealed that other

PT

poly-arginine peptides and CARPs as a group are highly neuroprotective, with efficacy
increasing with increasing peptide arginine content and positive charge, peaking at R15 to

RI

R18 for poly-arginine peptides [219]. In addition, we have demonstrated that different amino

SC

acids can increase (e.g. tryptophan) or decrease (e.g. alanine) the neuroprotective efficacy of
CARPs following glutamate excitoxicity [257], and that CARPs can reduce excitotoxic

NU

neuronal calcium influx and cell surface expression of the NR2B NMDA receptor subunit
protein [221]. Interestingly, it appears that the ability of CARPs to traverse cellular
membranes is correlated to peptide neuroprotective efficacy [161, 219, 257]. While the exact

MA

reason for this correlation is not fully known, it may be related to the ability of CARPs to
modulate plasma receptor function or expression levels [216, 218, 258], and/or the ability of

ED

CARPs to reach therapeutic concentrations within the cell cytosol and organelles (e.g.
mitochondria, nucleus, endoplasmic reticulum) by virtue of their cationic charge.
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The neuroprotective properties of CARPs, including poly-arginine peptides, was further
validated by Marshall et al (2015), who demonstrated the ability of CARPs to reduce
NMDA-induced retinal ganglion cell death in the retina of rats. In addition, an R7 poly-
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arginine peptide with a cysteine di-sulphide bridge (C-s-s-C-R7: C-s-s-CRRRRRRR-NH2)
reduced mitochondrial oxidative stress in retinal ganglion cells following NMDA exposure,
and localised to mitochondria in HEK293 cells. Furthermore, in HEK cells R7 and C-s-s-CR7 reduced mitochondrial respiration, m, and ROS generation, and it was proposed that
these effects on mitochondria would be neuroprotective for neurons during metabolic stress
(e.g. excitotoxicity and ischaemia) [264].

With respect to stroke, we have demonstrated in experimental studies in the rat that the polyarginine peptides R9D, R12, R18, R18D (D = D-isoform) and protamine all reduce infarct
volume following permanent and/or transient middle cerebral artery occlusion (MCAO) and
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perinatal hypoxia-ischaemia, and also reduce the severity of traumatic brain

injury [162,

265–269], further confirming the efficacy of CARPs in a pre-clinical stroke setting.

TAT and other cationic arginine-rich CPP-fused neuroprotective peptides
The TAT peptide was first characterised for its cell penetrating properties by Frankel and
Pabo (1988) [270]. Since then, many studies have used TAT and related cationic argininerich CPPs (CCPPs) (e.g. R9, penetratin) fused to “putative” neuroprotective peptides for

PT

application in stroke and other acute CNS injury pre-clinical neuroprotection studies, with
most returning positive results [258, 260, 261, 271–276]. However, given the unequivocal

RI

neuroprotective properties of CARPs, several years ago we proposed that the neuroprotective

SC

effects of “putative” neuroprotective peptides fused to CCPPs, which are CARPs, was
largely, if not exclusively mediated by the carrier peptide [219, 257]. In this context, it is also

NU

likely that the cargo peptide can further enhance the neuroprotective efficacy of CCPPs by
providing additional arginine residues, other positively charged amino acids (e.g. lysine) or
amino acids that increase CARP neuroprotective efficacy (e.g. tryptophan), as well as

MA

providing structural stability. Importantly, studies in our laboratory [219, 221, 257] and by
Marshall et al. (2015), and more recently McQueen et al. (2017), support a CARP-mediated

ED

neuroprotective mechanism for “putative” neuroprotective peptides fused to CCPPs (e.g.
TAT-NR2B9c and TAT-NR2Bct) [264, 277] (for more detail on this subject, see Meloni et
al. 2015b). Therefore, based on the findings from our and other laboratories, we believe that
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past neuroprotective studies that have utilized CCPPs need to be critically re-evaluated.

Despite the confounding neuroprotective effects of the carrier peptide in studies using
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“putative” neuroprotective peptides fused to CCPPs, it is likely that due to their cationic and
arginine-rich properties, these peptides have the capacity to target and exert beneficial effects
on neuronal mitochondria following stroke. While it will be important for future studies to
confirm the mito-protective properties of neuroprotective peptides fused to CCPPs, it is
encouraging that so many studies have returned positive results in stroke and other acute and
chronic neuronal injury models [226, 256, 274, 278–291]. To this end, the TAT-fused
neuroprotective peptide TAT-NR2B9c, now known as NA-1, is currently being assessed in
two Phase III clinical stroke trials (ESCAPE-NA-1 and FRONTIER). It is noteworthy in this
regard that based on studies from our and other laboratories, other CARPs including polyarginine peptides (e.g. R18) display even greater neuroprotective efficacy than NA-1 in
stroke and related neuronal injury models [162, 257, 264, 265, 267].
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Borna disease virus X protein
The X protein derived from the Borna virus (BVD-X) is a cationic protein containing 11
arginine residues that has mitochondriotropic and mito-protective capabilities. It was
demonstrated to localise in mitochondria in rat C6 astroglioma cells, and was shown to
prevent apoptosis in response to both extrinsic (10 µg/mL α-Fas) and intrinsic (50 µM

PT

peroxynitrite) pathway stimuli in HEK293T and mouse L929 cells, respectively [292].

In relation to neuroprotection, Szelechowski et al. (2014) demonstrated that in neurons over-

Furthermore

BVD-X

preserved

mitochondrial bioenergetics

by

SC

axonal fragmentation.

RI

expressing BVD-X, the protein localised to mitochondria and reduced rotenone–induced
preventing rotenone-induced loss of Δψm and subsequent ROS generation. In addition, it was

NU

demonstrated that when administered stereotaxically into the substantia nigra pars compacta,
BVD-X provided neuroprotection in a mouse MPTP Parkinson’s disease model [293]. A
peptide derived from BVD-X (SRPAPEGPQEEPLHDLRPRPANRKGAAVE) and fused to a

MA

CCPP and mitochondrial penetrating peptide (FRchaKFRchaK; cha = cyclohexyl-alanine),
termed PX3, (net charge +4.1, arginine residues = 6), when administered intranasally also
MPTP-induced

neurodegeneration

in

mice.

PX3

also

accumulated

within

ED

reduced

mitochondria of cultured neurons and protected axons against rotenone-induced axonal
fragmentation, which corresponded to reduced levels of mitochondrial fission and the

EP
T

retention of a greater proportion of filamentous over fragmented mitochondria within
neurons. Interestingly, both BVD-X and PX3 were shown to reduce Drp1 phosphorylation in
neurons exposed to rotenone, which is a signalling event known to stimulate mitochondrial
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fission [293]. In a subsequent study, the same group demonstrated that introduced mutations
of the BVD-X protein designed to enhance mitochondrial localization resulted in greater
efficacy against rotenone-induced mitochondrial stress in cortical neuronal cultures, an effect
that correlated with enhanced mitochondrial filamentation and reduced fragmentation [294].

It is important to note that while the efficacy of the BVD-X derived peptide PX3 has yet to be
explored in stroke injury models, its neuroprotective actions in terms of maintaining
mitochondrial structural integrity provides further insight into the potential mechanisms
whereby CARPs may be neuroprotective in stroke.

4.

Conclusions and Future Perspectives
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With ischaemic stroke constituting one of the leading causes of global morbidity and
mortality,

the development of effective neuroprotective therapeutics is of paramount

importance and an urgent priority. Mitochondria are an exciting focus for developing novel
neuroprotective agents, particularly in view of the critical role they play in homeostatic
cellular processes, including the generation of cellular ATP and regulation of intracellular
calcium homeostasis. Furthermore, as a consequence of cerebral ischaemia, damaged

PT

mitochondria play a key role in contributing to oxidative stress and the activation of prodeath signalling cascades in neurons post-ischaemia. At present, CARPs represent an exciting

RI

new class of pluripotent therapeutic for acute stroke due to their mitochondria-targeting and

SC

mitoprotective properties, as well as other neuroprotective actions. In particular, polyarginine peptides (such as R18 and R18D), which have been shown to have potent
properties

in

experimental stroke models,

warrant further preclinical

NU

neuroprotective

evaluation prior to progressing to clinical trials. In addition, due to their multiple
neuroprotective

mechanisms of action,

CARPs may have broader potential clinical

MA

application for the treatment of other forms of acute brain injury, as well as chronic

ED

neurodegenerative disorders.
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Figure Legends

PT

Figure 1. Major biochemical pathways of the ischaemic cascade, which inevitably lead to
irreversible cell death via apoptosis and necrosis. Insufficient oxygen for aerobic energy
ATP

levels,

necessary for preservation of critical

RI

production results in diminished

triggers

mass

release

of excitatory

SC

homeostatic functions, particularly maintenance of cellular ionic gradients. This disruption
neurotransmitters,

which

overstimulates

calcium-

NU

permeable ion channel receptors on post-synaptic neurons, causing massive calcium influx.
This in turn triggers a number of key destructive events, collectively known as the ischaemic
cascade, and include activation of calcium-sensitive proteases, free radical formation, and

MA

mitochondrial dysfunction. Mitochondria are central modulators in this cascade, and are both
targets and contributors of the resulting injurious effects.
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AMPA,  -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; ASIC, acid-sensing ion
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channel; Apaf-1, apoptotic protease activating factor 1; CICR, calcium-induced calcium
release; cyt c, cytochrome c; CypD, cyclophilin D; ER, endoplasmic reticulum; I-V,
mitochondrial ETC complexes; IP ₃ R, inositol triphosphate receptor; MCU, mitochondrial
calcium uniporter; MAM, mitochondria associated membranes; mNCX, mitochondrial
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sodium-calcium exchanger; mPTP, mitochondrial permeability transition pore; mRyR,
mitochondrial ryanodine receptor; NCX, sodium-calcium exchanger; NMDA, N-methyl-Daspartate; PMCA, plasma membrane Ca²⁺ -ATPase; RaM, rapid mode calcium uptake; RyR,
ryanodine receptor, TRPM, transient receptor potential ion channel; Smac, second
mitochondria-derived activator of caspase; VDAC, voltage-dependent anion channel.
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Figure 2. Mitochondrial ROS generation contributes to oxidative stress during ischaemic
stroke. The IMM contains mitochondrial complexes I to V, which comprise the ETC.
Electrons are transferred along the ETC in a stepwise fashion via electron carriers, including

PT

CoQ and cyt c, thereby releasing protons (H⁺ ) into the IMS. This accumulation of cations
comprises the mitochondrial membrane potential (Δψm), which is required for ATP

RI

production by complex V. This process naturally generates low levels of ROS as a by-

SC

product, which are metabolized by endogenous catabolic enzymes. However, during
ischaemic stroke additional cellular stress turns mitochondria into the largest contributor of

NU

ROS in the brain. Consequently, electron ‘leak’ from complexes I and III are responsible for
excess superoxide radical (O₂ •⁻ ) formation, which further reacts with endogenous
manganese superoxide dismutase (MnSOD), or undergoes spontaneous dismutation to form

MA

toxic levels of hydrogen peroxide (H₂ O₂ ). H₂ O₂

subsequently reacts with transitional

metals to further form hydroxyl radicals (•OH) via the Fenton reaction. Furthermore, NO•

ED

generated from nNOS as a result of calcium influx during ischaemic stroke are able to
translocate to the mitochondria and react with O₂ •⁻ to form the highly toxic peroxynitrite

during stroke.
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(ONOO⁻ ). Collectively, the overproduction of these ROS plays a key role in cell death

CL, cardiolipin; CoQ, Coenzyme Q; e⁻ , electrons; H₂ O₂ , hydrogen peroxide; IMM, inner
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mitochondrial membrane; I-V, mitochondrial ETC complexes; IMS, intermembrane space;
NO•, nitric oxide; O₂ •⁻ , superoxide; •OH, hydroxyl radical; OMM, outer mitochondrial
membrane; ONOO⁻ , peroxynitrite; Δψm, mitochondrial membrane potential.

Figure 3. Neuroprotective targets of CARPs during ischaemic stroke. A summation of
documented and potential neuroprotective targets of CARPs that result from either direct
and/or indirect mitochondrial protection, thereby preventing cell death.
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Table 2. Neuroprotective CARPs utilized in stroke and related CNS injury models.

Injury model

H2 O2 oxidative
stress.

Neuroprotection

SS-31: 10 µM.
SS-31: 1, 10, 100 µM.

1h post H2 O2.

Reduced cell death, cytochrome c release,
oxidative stress, and caspase-3 activation;
prevented p66Shc activation.
Reduced cell death.

SS-31: 5 mg/kg/day.

Stroke (Rat):
30min pMCAO.

90min tMCAO.
120min tMCAO.
180min tMCAO.
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NMDA
excitotoxicity.

Kainic acid
excitotoxicity.

R6 to R15, R18 and
tryptophan-containing polyarginine peptides 0.5-15 µM.
R18 or R12W8: 1000
nmol/kg; R9D; 30 nmol/kg.
R12, R15, or R18: 1000
nmol/kg; R18 and R18D:
1000 nmol/kg.
R18: 100, 300, 1000
nmol/kg.
R18: 1000 nmol/kg.
R18: 30, 100, 300, 1000
nmol/kg.
R18: 100 nmol/kg R18.
R18: 1000 nmol/kg R18.

IV: 60min postMCAO onset.
IV: 120min
post-MCAO
onset.
IV: 150min
post-MCAO
onset.
ICA: 120min
post-MCAO
onset.
IV: 300min
post-MCAO
onset.
5min prior and
during NMDA
exposure.
Intravitreal
injections (3
µL) of C-s-sC-R7 peptide
2h prior to

R12: 1 or 2 µM R12.
Cyclic poly-arginine
peptides: 1.5, 3, 6 nM.
R9: 1, 5, 10, 15 µM.

[251]

PT

Protected against excitotoxicity and reduced
calcium influx.

[156,
160,
161,
256]
[219]

RI

R6 to R15, R18 and
tryptophan-containing polyarginine peptides 0.5-15 µM.

[250]

[253]

SC

10-15min
peptide pretreatment
and/or during
glutamate
exposure.
10min peptide
pre-treatment
at 1-6h prior
or 0-45min
postglutamate
exposure.
Concurrent
peptide
incubation with
OGD.
24h exposure
post-OGD.
15min exposure
post-OGD.
10min exposure
pre-OGD 1-3h
prior.
IV: 30min postMCAO onset.

SS-31 and SS-20: 2 mg/kg.
SS-31: 2 or 5 mg/kg.

Refs

[251]
Improved survival and motor performance;
reduced cell loss in spinal cord, and levels of
lipid peroxidation and protein nitration.
SS-31 only prevented ischaemia-induced
cortical GSH depletion; reduced infarct
volume

Protected against excitotoxicity up to 6h prior
to and 45min post-glutamate.
Protected against OGD.
Protected against OGD.
Protected against OGD.
Protected against OGD up to 2h prior.
Reduced infarct volume and cerebral oedema;
reduced hemisphere swelling.
R12 and R18, and to a greater extent, R18D,
reduced total infarct volume.
Reduced infarct volume and improved
functional outcomes.
Reduced cerebral oedema and improved
neurological score.
Reduced infarct volume and hemisphere
swelling.
Mild reduction in infarct volume.
Mild reduction in cerebral oedema and
improvement in neurological score with R18.
Protected against excitotoxicity.
Inhibited NMDA-induced PARP-1 activation;
reduced mitochondrial oxidative stress and
attenuated mitochondrial membrane
hyperpolarization.
Protected against excitotoxicity.

NU

Oxygen-glucose
deprivation.

IP: multiple
injections at
immediately
post (0h), 6,
24, & 48h
post-MCAO

MA

Glutamate
excitotoxicity.

IP: daily.

ED

G93A familial
ALS model.
Stroke (Rat):
30min tMCAO.

Poly-arginine peptides

Dose

EP
T

SS-peptides

Hypoxia: 24h.

Route and
schedule of
administration
4h pretreatment.

[219]
[256]
[219]
[219]
[161,
219]
[265,
269]
[266]
[267]
[162]
[267]
[267]
[219]
[264]
[256]
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Concurrent
treatment
with NMDA
exposure for
20min.

10-15min prior
to or at
intervals (0,
15, 30, 45, or
60min) post
glutamic acid
exposure.
15min prior to
kainic acid
exposure.
Concurrent
peptide
incubation.
Simultaneous
T AT
treatment or
15min prior
to and during
NMDA
exposure.
IV: 60min postMCAO onset.
IV: 150min
post-MCAO
onset.
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TAT and TAT-fused
peptides

Glutamate
excitotoxicity.
Kainic acid
excitotoxicity.
Oxygen-glucose
deprivation.
NMDA
excitotoxicity.
Stroke (Rat):
30min pMCAO.
90min tMCAO.
120min tMCAO.
180min tMCAO.

Protected against excitotoxicity.
Protected against excitotoxicity up to 2h prior
to glutamate.

NU

Penetratin: 1, 5, 10, 15 µM.
Penetratin: 1, 2, 5, 10 µM.
Protamine 1000 nmol/kg.
Hexapeptides: 10 µM.

MA

NMDA
excitotoxicity.

Penetratin: 1, 5, 10, 15 µM.
Protamine and Pmt1-4: 1, 2,
5 µM

Protected against excitotoxicity.
Protected against OGD.
Reduced infarct volume and cerebral oedema;
improved neurological score.
Protected against excitotoxicity.

[256]
[161]
[256]
[256]
[161]
[262]

ED

Kainic acid
excitotoxicity.
Oxygen-glucose
deprivation.
Stroke (Rat):
30min pMCAO.

15min prior to
glutamic acid
exposure.
10min peptide
incubation 0,
1, and 2h
prior to
glutamic acid
exposure.
15min prior to
kainic acid
exposure.
Concurrent
peptide
incubation
with OGD.
IV: 30min postMCAO onset.

EP
T

Penetratin, Protamine and Hexapeptides

Glutamate
excitotoxicity.

SC

RI

PT

successive
injection with
NMDA (20
nM).
15min pretreatment.

T AT or TAT-conjugated
peptides, both L- and Disoforms: 0.1-15 µM; T ATNR2B9c: 1, 2, 5, 10 µM.
D-T AT and TAT-conjugates:
1-15 µM.
D-T AT: 1, 2, 5, 10 µM.
T AT and D-TAT pretreatment: 5, 10 µM;
T AT -NR2B9c: 2, 5, 10 µM.
T AT -NR2B9c: 100, 300,
1000 nmol/kg.
T AT -NR2B9c: 30, 100, 300,
1000 nmol/kg.
T AT -NR2B9c: 100 nmol/kg.
T AT -NR2B9c: 1000
nmol/kg.

Protected against excitotoxicity.
Reduced calcium influx.
Protected against OGD.
Protected against excitotoxicity.
Reduced infarct volume and improved
functional outcomes.
Mild reduction in infarct volume and
hemisphere swelling.
No neuroprotection.
No neuroprotection; therapeutic window <2h.

[219,
256,
258,
259]
[256]
[219,
256]
[219]
[266]
[162]
[267]
[267]
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ICA: 120min
post-MCAO
onset.
IV: 300min
post-MCAO
onset.

[291]

T ransfection.

Reduced receptor-independent,
mitochondrial-dependent apoptosis.

[291]

1.10 6 T Us of vectors in 1 μl
at flow rate of 0.1 μl/min.

Reduced lesions and protection against
MPT P-induced neurodegeneration.

[292]

Reduced lesions and protection against
MPT P-induced neurodegeneration.

[292]

Reduced lesions and protection against
MPT P-induced neurodegeneration.

[292]

Reduced axonal fragmentation.

[292]

Increased mitochondrial filamentation and
elongation, and reduced rotenone-induced
fission, and reduced axonal fragmentation.
Neuroprotection against axonal fragmentation
and reduced rotenone-induced ROS and
oxidative stress with WT only.
Near-complete prevention of rotenoneinduced axonal fragmentation.

[292]

T ransfection.

T ransfection or PX3 peptide
treatment
T ransfection.
T ransfection.

RI

NU

T ransfection or PX3 peptide
treatment.

SC

T ransfection or PX3 peptide
treatment (2 nM in 2
µL/injection at flow rate of
0.5 μl/min.

PT

Reduced DX2-Fas-induced apoptosis.

EP
T

Rotenone-induced
oxidative
stress.
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BVD-X protein and PX3 peptide

MPP+ toxicity.

Stereotaxic
injection
with WT
(LV-XWT) or
mutant X
protein
(XA6A7 ) 2wk
prior to
MPT P
intoxication
model.
ICV: PX3
daily, 1 day
before IP
MPT P
intoxication
and during
first 4 days
post-MPTP.
Intranasal
administratio
n: PX3 daily,
1 day before
IP MPTP
intoxication
and during
first 4 days
post-MPTP.
WT (BVDWT)
or mutant
(BDV-XA6A7)
X protein.
WT or mutant
X protein
(XA6A7 ), or
untransfected
neurons
receiving
PX3 peptide.
WT (BVDWT)
or mutant
(BDV-XA6A7)
X protein.
Neurons
expressing
nonmitochondria
l XA6A7
(control) or
mutant X

T ransfection.

MA

Glucose oxidase
(GOX)induced deathreceptorindependent
apoptosis.
MPT P PD
neurodegenerat
ion model
(Mouse)

10µg/mL α-Fas
antibody to
stimulate Fasinduced
apoptosis.
1.5 or 2h
incubation
with
2mU/mL
GOX.

ED

Fas-mediated
apoptosis.

[292]
[293]
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RI

PT

proteins (X,
XΔ2-4 and
XA4 ).
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MA

NU

ICA = intracerebral artery; ICV = intracerebral vessel; IP = intraperitoneal; IV = intravenous; MCAO = middle cerebral artery occlusion; OGD =
oxygen-glucose deprivation; PD; Parkinson’s disease.
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Highlights


There are currently no clinically effective neuroprotective therapeutics available for
stroke patients.



Mitochondria have been highlighted as a critical central mediator in determining the
cellular fate of neuronal and glial cells during stroke.



Cationic

arginine-rich

peptides

(CARPs)

are

an

emerging

class

of

novel

PT

neuroprotective agents that have demonstrated potent neuroprotection by targeting
mitochondria during stroke.
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ED

MA

NU

SC

translate to better clinical outcomes in stroke trials.

RI

Mito-protection may represent a new avenue of targeted drug development, and
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